Top Menu

Author Archive | Bob Ehrlich

Bob Ehrlich

DTC in Perspective: DTC Might Be Imperfect, But Still Important for Patients

Drug companies defend DTC by arguing it creates disease awareness and information on treatment options. Critics of DTC say it pushes high price drugs and creates undue pressure on physicians to prescribe branded drugs when alternative treatments are just as good. An article in the March 23 issues of US News and World Report written […]

Continue Reading 0
Bob Ehrlich

DTC in Perspective: Spending Tops $5 Billion in 2015, Up 14% vs. 2014

DTC spending continued its strong comeback in 2015, following a strong 2014. Spending was $5.17 billion in 2015 according to Nielsen, the best performance since 2007 when $5.33 billion was spent. Fueled by many new product launches, DTC advertisers spent heavily in 2015. Some of the biggest newer spenders were Xifaxan, Toujeo, Belsomra, Breo Ellipta, […]

Continue Reading 0
Bob Ehrlich

DTC in Perspective: The Consequences of Attacking Drug Profits

There are several candidates talking about the high costs of drugs. The Republican front-runner, Donald Trump, has said in his town halls that we could save $300 billion a year by negotiating pricing through competitive bidding. Bernie says drug companies make outrageous profits and through a single payer system, he would dramatically lower costs. Hillary […]

Continue Reading 0
Bob Ehrlich

DTC in Perspective: Novartis Heart Failure Ad Gets Criticized

Novartis has just started a non branded disease education campaign called “Keep it Pumping.” You can see the television ad on the Novartis web site: www.keepitpumping.com. This Novartis web site discusses the serious condition of heart failure which has only a 50% survival rate after five years from diagnosis. The ad is very memorable, showing […]

Continue Reading 0
Bob Ehrlich

DTC in Perspective: Cosentyx DTC Joins Psoriasis Battle

The television campaign for plaque psoriasis fighter Consentyx started in January. The new drug from Novartis is joining Humira, Otezla, Stelara, Remicade and Enbrel. All have been DTC advertisers in a market affecting about 7.5 million Americans. Cosentyx is taking an interesting DTC creative approach. It is using testimonials from real patients who ask others […]

Continue Reading 0